Compounds > ro 12-5637
Page last updated: 2024-12-08

ro 12-5637

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ro 12-5637: metabolite of moclobemide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID163052
SCHEMBL ID7640103
MeSH IDM0173953

Synonyms (15)

Synonym
64544-24-7
4-chloro-n-[2-(4-oxidomorpholin-4-ium-4-yl)ethyl]benzamide
4-chloranyl-n-[2-(4-oxidanidylmorpholin-4-ium-4-yl)ethyl]benzamide
A837738
4-chloro-n-[2-(4-oxido-4-morpholin-4-iumyl)ethyl]benzamide
ro-12-5637
benzamide, 4-chloro-n-(2-(4-morpholinyl)ethyl)-, n-oxide
ro 12-5637
SCHEMBL7640103
DTXSID20983169
4-chloro-n-[2-(4-oxo-1,4lambda~5~-oxazinan-4-yl)ethyl]benzamide
moclobemide n-oxide
benzamide, 4-chloro-n-[2-(4-oxido-4-morpholinyl)ethyl]-; benzamide, 4-chloro-n-[2-(4-morpholinyl)ethyl]-, n-oxide; 4-chloro-n-[2-(4-oxido-4-morpholinyl)ethyl]benzamide; ro 12-5637; moclobemide n-oxide
HY-135265
AKOS040753776

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" To confirm the involvement of CYP2C19, we performed a pharmacokinetic interaction study."( Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
Bae, KS; Cho, JY; Jang, IJ; Lee, KH; Park, JY; Park, SS; Shin, SG; Yi, SY; Yim, DS; Yu, KS, 2001)		0.31
" On the eighth morning, 300 mg of moclobemide and 40 mg of placebo were coadministered with 200 mL of water, and a pharmacokinetic study was performed."( Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
Bae, KS; Cho, JY; Jang, IJ; Lee, KH; Park, JY; Park, SS; Shin, SG; Yi, SY; Yim, DS; Yu, KS, 2001)		0.31
" After daily administration of omeprazole for 1 week, the pharmacokinetic parameters of moclobemide and its metabolites in extensive metabolizers changed to values similar to those in poor metabolizers."( Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
Bae, KS; Cho, JY; Jang, IJ; Lee, KH; Park, JY; Park, SS; Shin, SG; Yi, SY; Yim, DS; Yu, KS, 2001)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's4 (80.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
moclobemide
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.		4.4851benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		3.3911aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
ro 12-8095
Ro 12-8095: metabolite of moclobemide		4.341
ConditionIndicatedRelationship StrengthStudiesTrials
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0310